Core Viewpoint - The approval of the new indication for the reversible Bruton's tyrosine kinase (BTK) inhibitor, Pirtobrutinib, represents a significant advancement in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously undergone systemic therapy including BTK inhibitors [1][2] Group 1: Product Approval and Mechanism - Pirtobrutinib has received approval from the National Medical Products Administration (NMPA) in China for use in adult CLL/SLL patients who have previously been treated with at least one systemic therapy including BTK inhibitors [1] - Pirtobrutinib is a highly selective kinase inhibitor that employs a novel binding mechanism, allowing it to restore BTK inhibition in patients previously treated with covalent BTK inhibitors [1] Group 2: Clinical Study Results - The approval is based on the results of the international multicenter, randomized controlled BRUIN CLL-321 Phase III study, which included 238 patients [2] - The study demonstrated that Pirtobrutinib significantly extended the median progression-free survival (PFS) to 14.0 months compared to 8.7 months for the control group, with a hazard ratio (HR) of 0.54 [2] - The treatment-related discontinuation rate for Pirtobrutinib was lower at 5.2% compared to 21.1% for the control group, confirming its efficacy and tolerability advantages in the population previously treated with covalent BTK inhibitors [2] Group 3: Market Impact and Future Plans - The approval of Pirtobrutinib for CLL/SLL in China marks a major breakthrough, allowing local patients to benefit from this global innovation [2] - The company aims to leverage its leading brand and expertise in oncology to accelerate the accessibility of this innovative therapy for more patients in need [2]
信达生物：捷帕力 (匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症